Phosphodiesterase inhibitors for pulmonary hypertension

N Engl J Med. 2010 Feb 11;362(6):559; author reply 560. doi: 10.1056/NEJMc0912127.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Humans
  • Hypertension, Pulmonary / drug therapy
  • Hypertension, Pulmonary / etiology*
  • Phosphodiesterase 5 Inhibitors*
  • Phosphodiesterase Inhibitors / adverse effects
  • Phosphodiesterase Inhibitors / therapeutic use*
  • Piperazines / therapeutic use
  • Pulmonary Edema / chemically induced
  • Pulmonary Veno-Occlusive Disease / complications*
  • Pulmonary Veno-Occlusive Disease / diagnosis
  • Pulmonary Veno-Occlusive Disease / therapy
  • Purines / therapeutic use
  • Sildenafil Citrate
  • Sulfones / therapeutic use
  • Ventricular Dysfunction, Left / complications*

Substances

  • Phosphodiesterase 5 Inhibitors
  • Phosphodiesterase Inhibitors
  • Piperazines
  • Purines
  • Sulfones
  • Sildenafil Citrate